drugset / Trial / NCT00562952

Nt-proBNP Guided Primary Prevention of CV Events in Diabetic Patients

NCT00562952

Phase 2/3 Completed 300 enrolled Medical University of Vienna Roche Pharma AG · collab
RandomizedParallel-groupOpen-labelPrevention

Summary

Increased levels of NT-proBNP are known to increase the risk of cardiac events in diabetic patients. The other way around, patients with normal values have an excellent prognosis on short-term. We intend in our study to proof the hypothesis, whether it is possible to decrease NT-proBNP levels by intensified cardiac prevention care We aim those patients, who already have elevated levels, although no history of a cardiac disease. This decrease in NT-proBNP should be translated consequently in a decrease in cardiac events

Timeline

Start
2007-11
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bisoprolol Other / unclassified
Comparator Telmisartan Other / unclassified